Metagenomi and Moderna Terminate Gene-Editing Collaboration
Metagenomi and Moderna have concluded their gene-editing partnership, resulting in Metagenomi reclaiming full rights to its gene-editing technologies, including base editors and RNA-mediated integration systems. Moderna's decision to reprioritize its programs led to this termination. Despite going public in February and raising $94 million, Metagenomi remains a Moderna shareholder, with Moderna retaining a 4.6% stake post-IPO and Bayer holding a 10.8% stake.
Key Takeaways
- Termination of Metagenomi and Moderna's gene-editing collaboration, including the primary hyperoxaluria type 1 program.
- Metagenomi now possesses complete global rights to its gene-editing technologies, comprising base editors and RNA-mediated integration systems.
- Reprioritization of programs at Moderna drove the collaboration's termination.
- Metagenomi's public offering in February raised $94M, leaving Moderna with a 4.6% stake post-IPO.
- Bayer holds a 10.8% stake in Metagenomi.
Analysis
The termination of the gene-editing collaboration between Metagenomi and Moderna has ramifications for both companies and their stakeholders. Moderna's reprioritization enabled Metagenomi to regain full control of its technologies, including base editors and RNA-mediated integration systems. However, the loss of resources from Moderna could potentially impede progress. In the short term, this decision grants Metagenomi autonomy over technology development and potential partnerships. Yet, it may lead to delays due to the absence of Moderna's resources. Looking ahead, new collaborative opportunities may emerge for Metagenomi, while the focus of Moderna's gene editing remains uncertain. The financial instruments of both companies, such as their stocks, may be affected as investors evaluate risks and potential outcomes. Consequently, this split could drive innovation in gene editing and create openings for collaboration, influencing the gene-editing and biotech industries as a whole.
Did You Know?
- Gene-editing: A form of genetic engineering involving the direct manipulation of an organism's genes using engineered nucleases, such as CRISPR/Cas9, zinc finger nucleases, and TALENs. These engineered nucleases can be programmed to cut DNA at specific locations, enabling precise modification of the genome.
- Base editors: A gene-editing technology facilitating precise and efficient modification of individual bases (A, T, C, and G) in the genome without creating double-strand breaks. It holds potential for correcting point mutations causing genetic diseases, without the risk of inducing unwanted insertions or deletions.
- Metagenomi: A biotech company focused on developing novel gene-editing technologies, including base editors and RNA-mediated integration systems. The company went public in February 2023 and collaborated with Moderna to develop gene therapies for genetic diseases like primary hyperoxaluria type 1.